Elevation of high-density lipoprotein cholesterol in humans during long-term therapy with amiodaroneP T Pollak
Department of Medicine, Dalhousie University, Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia, Canada
Am J Cardiol 83:296-300, A7. 1999
....
- Quetiapine fumarate overdose: clinical and pharmacokinetic lessons from extreme conditions
P T Pollak
Department of Medicine, Queen Elizabeth II HSC, Dalhousie University, Halifax, Nova Scotia, Canada
Clin Pharmacol Ther 68:92-7. 2000
..Observation of an overdose situation provided a unique opportunity to define the safety, clinical effects, and pharmacokinetics of this medication more clearly...
- Determination of plasma concentrations of losartan in patients by HPLC using solid phase extraction and UV detection
P K Yeung
Pharmacokinetics and Metabolism Laboratory, College of Pharmacy, Faculty of Health Professions, Dalhousie University, Halifax, NS, Canada
Int J Pharm 204:17-22. 2000
..To establish a HPLC assay for plasma losartan and its active metabolite EXP3174 to facilitate clinical pharmacokinetic studies...
- Sertraline-induced hypoglycemia
P T Pollak
Department of Medicine, College of Pharmacy, Dalhousie University, Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada
Ann Pharmacother 35:1371-4. 2001
..To report a case of hypoglycemia that occurred in a patient treated with the selective serotonin-reuptake inhibitor, sertraline...
- Therapeutically relevant blood pressure differences with two nifedipine (60 mg) osmotic delivery systems of differing design: three case reports
P T Pollak
Departments of Medicine, Cardiac Sciences, and Physiology and Pharmacology, University of Calgary, Calgary, Canada
Int J Clin Pharmacol Ther 48:400-4. 2010
..In at least some patients, the alternate pump technology appears less effective. This highlights the need for better bioequivalence criteria for comparing differing delivery technologies that artificially retard absorption of the drug...
The use of amiodarone for in-hospital cardiac arrest at two tertiary care centresP Timothy Pollak
Department of Medicine, Dalhousie University, Halifax, Nova Scotia
Can J Cardiol 22:199-202. 2006
..Although amiodarone significantly increases survival to hospital admission when used in resuscitation of out-of-hospital pulseless ventricular tachycardia and fibrillation, there are limited data on its utility for in-hospital arrests...
- Use of population modeling to define rational monitoring of amiodarone hepatic effects
P Timothy Pollak
Department of Medicine, Queen Elizabeth II Health Sciences Centre, Dalhousie University, Halifax, Nova Scotia, Canada
Clin Pharmacol Ther 75:342-51. 2004
..Amiodarone causes hepatotoxicity in experimental models, but in humans, the relationships between drug administration, serum concentrations, markers of liver function, and how to monitor for hepatotoxicity have not been well characterized...
- Monitoring of hepatic function during amiodarone therapy
P Timothy Pollak
Department of Medicine, Dalhousie University, Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia, Canada
Am J Cardiol 91:613-6. 2003
- Altered metabolite concentrations with amiodarone generic substitution cannot be observed without monitoring
P T Pollak
Dalhousie University, Queen Elizabeth II Health Sciences Centre, Halifax, Canada
Can J Cardiol 17:1159-63. 2001
..Physicians should monitor patients for several months after a switch in amiodarone formulation is made. Regulatory criteria for bioequivalence of amiodarone need to be reconsidered...
- Population pharmacokinetics of long-term oral amiodarone therapy
P T Pollak
Department of Medicine Dalhousie University, Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada
Clin Pharmacol Ther 67:642-52. 2000
..Amiodarone is an increasingly popular and uniquely effective antiarrhythmic agent for which population pharmacokinetic parameters in patients receiving long-term oral therapy have not been defined previously...
